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A significant unmet need exists for accurate, reproducible, noninvasive diagnostic tools to assess and monitor portal hypertension
(PHT).We report the first use of quantitativeMRImarkers for the haemodynamic assessment of nonselective beta-blockers (NSBB)
in PHT. In a randomized parallel feasibility study in 22 adult patients with PHT and a clinical indication for NSBB, we acquired
haemodynamic data at baseline and after 4 weeks of NSBB (propranolol or carvedilol) using phase-contrast MR angiography (PC-
MRA) in selected intra-abdominal vessels. T1 mapping of liver and spleen was undertaken to assess changes in tissue composition.
Target NSBB dose was achieved in 82%. There was a substantial reduction from baseline in mean average flow in the superior
abdominal aorta after 4 weeks of NSBB therapy (4.49 ± 0.98 versus 3.82 ± 0.86 L/min, 𝑃 = 0.03) but there were no statistically
significant differences in flow in any other vessels, even in patients with >25% decrease in heart rate (47% of patients). Mean
percentage change in liver and spleen T1 following NSBB was small and highly variable. In conclusion, PC-MRA was able to detect
reduction in cardiac output by NSBB but did not detect significant changes in visceral blood flow or T1. This trial was registered
with the ISRCTN registry (ISRCTN98001632).
1. Introduction
Structural changes within the cirrhotic liver, combined with
portal and systemic haemodynamic changes, lead to portal
hypertension (PHT) which underlies the majority of clin-
ical manifestations and complications of cirrhosis such as
varices, ascites, hepatorenal syndrome, and encephalopathy.
Currently, hepatic venous pressure gradient (HVPG) mea-
surement is the only validated method of assessing PHT and
evaluating the effect of pharmacological interventions. The
prognostic value of PHT measurement at different stages in
the natural history of cirrhosis is well established, with cut-
off values for the development of complications (HVPG >
10mmHg) and variceal rupture (HVPG > 12mmHg) [1, 2].
However, HVPGmeasurement is invasive and expensive and
is neither accessible nor used widely outside of specialist
centres. A recommendation from the Baveno V Consensus
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was to identify noninvasive tools for measuring PHT, which
could have clinical utility formonitoring changes in PHTover
time or in response to treatment [3].
A number of approaches have been investigated for the
noninvasive assessment of PHT encompassing routine labo-
ratory tests (e.g., platelets to spleen ratio [4]), serummarkers
of inflammation and fibrosis (e.g., sCD163 and Enhanced
Liver Fibrosis test [5]), quantitative assays of liver function
(e.g., dual cholate clearance [6], indocyanine green retention
[7]), and imaging techniques (e.g., transient elastography [8])
which have all shown varying levels of diagnostic accuracy.
Recently, magnetic resonance imaging (MRI) based tech-
niques have shown promise for investigating differential vis-
ceral blood flow in the hyperdynamic circulation of patients
with cirrhosis [9] and in quantifying PHT. For example, MRI
derived hepatic blood flow parameters and azygous flow have
been shown to correlate with portal pressure [10] and variceal
size [11], respectively. Furthermore, a recent study suggested
a predictive model of HVPG based on the combination of
MRI acquired splenic artery velocity and liver T1 relaxation
time [12].TheseMRImeasurements can be performed on 1.5-
tesla or 3-tesla scanners, potentially without contrast agents,
no breath-hold scans, and short scan times, all features which
increase the potential for the widespread adoption of the
technique across healthcare systems.
Nonselective beta-blockers (NSBB) reduce HVPG and
are, therefore, an established treatment in both primary
and secondary prophylaxis of variceal bleeding in cirrhosis,
either in combination with endoscopic band ligation or as an
alternative [13]. It has been repeatedly shown that less than
50% of patients achieve a successful haemodynamic response
to propranolol, which is in turn associated with an increased
risk of variceal bleeding [14, 15]. Perhaps unsurprisingly,
HVPG-guided drug therapy in PHT was recently shown to
achieve greater reduction in portal pressure leading to better
patient outcomes, including survival [16]. In addition to its
well-documented effect on portal pressure, data from animal
models also suggests that carvedilol may have an antifibrotic
and anti-inflammatory effect in liver parenchyma [17, 18],
potentially modifying extracellular matrix composition and
influencing liver T1 relaxation time.
We hypothesised that quantitative MRI derived haemo-
dynamic and structural markers, acquired noninvasively in a
single scan session, could be used to inform which patients
respond to NSSB therapy. Here, we report the findings of an
initial small feasibility study.
2. Patients and Methods
2.1. Study Design and Patient Population. This was a single-
centre, open-label, parallel study conducted at the Royal
Infirmary of Edinburgh from January 2015 to March 2016.
The study was conducted in accordance with the ethical
principles of the Declaration of Helsinki 2013 and Good
Clinical Practice guidelines. It was approved by NHS Lothian
Research and Development and the South East Scotland
Research Ethics Committee 02 (REC Reference: 14/SS/1050).
All patients gave written informed consent.
22 patients requiring prophylaxis of variceal haemorrhage
for cirrhotic PHT were randomized 1 : 1, by sealed opaque
envelope, to either carvedilol or propranolol treatment. Study
inclusion criteria were age 18–80 and presence of liver cirrho-
sis and PHT where commencement of NSBB was clinically
indicated. Study exclusion criteria were contraindication
to NSBB therapy (such as moderate to severe asthma) or
MRI scan; contraindication to administration of gadolinium-
based MRI contrast (including eGFR < 30mL/min); con-
comitant use of drugs used to treat PHT; previous TIPSS
insertion; portal vein thrombosis; hepatocellular carcinoma;
pregnancy or breastfeeding; and inability to obtain informed
consent.
2.2. Assessments. Upon enrolment, information on liver dis-
ease aetiology, past medical history, medication and alcohol
history, and results of the most recent upper gastrointestinal
endoscopy were recorded. Patients underwent a physical
examination and routine laboratory investigations (full blood
count, coagulation screen, and liver and renal function tests),
followed by the baseline MRI scan. Liver disease severity
was also assessed at baseline according to the Model for End
Stage Liver Disease (MELD) score and Child-Pugh score.
Starting doses of once-dailyNSBBwere 6.25mg for carvedilol
and 80mg for modified release propranolol. Patients’ com-
pliance with medication and adverse events monitoring were
assessed at an initial follow-up visit after 1 week of NSBB
therapy. Provided that NSBB were tolerated clinically and
haemodynamically (resting heart rate (HR) ≥ 50 beats per
minute (b.p.m), systolic blood pressure (SBP) ≥ 95mmHg),
the dose was escalated to the target once-daily dose of 12.5mg
of carvedilol or 160mg of propranolol. Further treatment
compliance and adverse events monitoring were assessed by
weekly telephone consultations. After 4 weeks, whilst on the
NSBB, the second MRI was performed. An interval of 4
weeks was chosen as haemodynamic responses to NSBB after
chronic use exceed the acute response rate [19]. Consistent
with previous landmark NSBB trial in PHT, treatment was
targeted at a resting HR reduction of more than 25% from
baseline [20]; this was defined as a clinical haemodynamic
response to NSBB (HR responders).
2.3. MRI. Patients were fasted for at least 4 hours prior to
MRI scans to avoid postprandial changes in splanchnic blood
flow. All patients had an estimated glomerular filtration rate
of more than 60mL/min and serum creatinine levels within
the normal range. The radiology team (radiographers, radi-
ologists, and MRI physicists) were blinded to the treatment
allocation.
MR imaging was obtained at the Edinburgh Imaging
Facility at Queen’s Medical Research Institute using a 3-tesla
Verio MRI system (Siemens Healthcare, GmbH, Erlangen,
Germany) with a combination of spine matrix and body
matrix coil elements. Firstly, we used electrocardiogram-
gated gadolinium (Gd; Gadavist 0.1mmol/kg) contrast-
enhancedMRA sequences to visualise the vessels and rapidly
identify the appropriate cross-section view of the vessel
of interest. Phase-contrast MR was then planned on the
appropriate view in order to determine flow rates within
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Table 1: Baseline characteristics of the study population.
Patient characteristic Treatment group
𝑃 value (propranolol versus
carvedilol)Propranolol MR Carvedilol All patients
Number 11 11 22 1.00
Age, years (mean ± SD) 56 ± 7 56 ± 10 56 ± 9 0.99
Male sex, 𝑛 (%) 10 (91) 8 (73) 18 (82) 0.28
Aetiology of liver disease
Alcoholic liver disease, 𝑛 (%) 5 (45) 3 (27) 8 (36) 0.39
Nonalcoholic fatty liver disease, 𝑛 (%) 3 (27) 4 (36) 7 (32) 0.66
Viral hepatitis, 𝑛 (%) 0 (0) 2 (18) 2 (9.1) 0.15
Other, 𝑛 (%) 3 (27) 2 (18) 5 (23) 0.62
Child-Pugh Score, 𝑛 (%)
Child-Pugh A 7 (64) 6 (55) 13 (59) 0.67
Child-Pugh B 2 (18) 3 (27) 5 (23) 0.62
Child-Pugh C 2 (18) 2 (18) 4 (18) 1.00
Baseline heart rate, bpm 78 (69–81) 82 (72–94) 79 (69–89) 0.14
Systolic BP, mmHg 128 (116–146) 136 (115–150) 136 (115–150) 0.99
Splenomegaly, 𝑛 (%) 8 (73) 8 (73) 16 (73) 1.00
Thrombocytopaenia, 𝑛 (%) 9 (82) 10 (91) 19 (86) 0.55
Final beta blocker dose (mg) 160 in 7 patients80 in 4 patients 12.5 in all —
Target beta blocker dose achieved, 𝑛 (%) 7 (64) 11 (100) 18 (82) 0.03
Completed study, 𝑛 (%) 9 (82) 10 (91) 19 (86) 0.55
Heart rate responders, 𝑛 (%) 5∗ (56) 4 (40) 9 (47) 0.50
∗Heart rate response in propranolol group was observed in 5 patients; 3 on 80mg of propranolol MR and 2 on 160mg of propranolol MR.
that vessel, as previously described [9]. Assessment of flow
rates was performed in the following vessels: proper hep-
atic artery, portal vein, superior mesenteric artery, superior
aorta (acquired 2 cm above the coeliac trunk), inferior aorta
(acquired 2 cm above the iliac bifurcation), renal arteries, and
azygous vein, as previously described [9]. 2-D PC blood flow
was analysed by two independent observers experienced in
PC-MRA, using Siemens Argus Flow software, as previously
described [9].
In addition, we assessed liver and spleen T1 relaxation
time mapping using an established protocol [21].
2.4. MRI T1 Analysis. Analysis of the pre-Gd T1 maps of
liver and spleen was performed, with the aim of identifying
a change in the T1 value between the pre- and posttreatment
scans. The images were analysed by a single operator using
LiverMultiScan software (Perspectum Diagnostics, Oxford,
UK). T1 values representing the mode of a segmented
liver/spleen slice histogram were used for analysis. In addi-
tion, 3 regions of interest (ROI) were positioned manually
within the liver/spleenT1maps and themean values of 3 ROIs
were used for further analysis.
2.5. Statistical Analysis. A sample size of 20 patients per
group was calculated as sufficient to create a 90% confidence
interval on themean change frombaseline thatwould exclude
the zero if a 25% change was observed for that parameter,
assuming the observed baseline mean and standard devia-
tion for the study was similar to the historically observed
standard deviation [9]. Following problems with patient
recruitment and extended study staffing, the target sample
size was reduced to 10 patients per group (i.e., total of 20
completed patients), supported by blinded interim analysis
on 16 completed patient datasets which indicated that the
overall analysis of the reduced patient dataset would still
generate meaningful and valuable results.
Statistical analysis was performed using GraphPad Prism
version 6.0 (GraphPad Software, USA). Variables were sum-
marised as mean ± standard deviation (SD) if normally
distributed and as median with interquartile range (IQR)
if not. A comparison of numerical variables between the
groups was performed using paired Student’s t-test when the
samples were normally distributed and the Mann–Whitney
U-test when not. Chi-square test was used to compare cate-
gorical data. Association between two continuous variables
was assessed using the Pearson and Spearman correlation
coefficient, as appropriate. The variability of the liver and
splenic T1 data and the interobserver variability were assessed
using Bland-Altman plots. A 𝑃 value of less than 0.05 (two-
tailed) was considered statistically significant throughout.
3. Results
3.1. Demographic and Clinical Characteristics of Study Partic-
ipants. 22 patients were recruited during the study period
(Table 1). Most weremale (82%) with amean ± SD age of 56 ±
9 years. Commonest aetiologies of liver disease were alcohol
4 BioMed Research International
Table 2: Baseline and 4-week post-NSBB blood flow. Data shown as mean ± SD and analysed by paired t-test (𝑛 = 19).
Baseline blood flow (L/min) 4-week blood flow (L/min) 𝑃 value
Superior aorta 4.49 ± 0.98 3.83 ± 0.86 0.029
Inferior aorta 1.45 ± 0.63 1.30 ± 0.53 0.41
Superior mesenteric artery 0.58 ± 0.20 0.56 ± 0.21 0.76
Proper hepatic artery 0.35 ± 0.23 0.33 ± 0.27 0.85
Total renal arterial 0.82 ± 0.34 0.64 ± 0.32 0.079
Portal vein 1.05 ± 0.61 0.83 ± 0.31 0.17
Azygos vein 0.30 ± 0.23 0.25 ± 0.16 0.49
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Figure 1: Bland-Altman plot of percentage differences in average
blood flow measurements between the two observers against the
mean blood flow. The bias between the 2 sets of measurements was
small (0.2% or 0.05 L/min; limits of agreement −0.23 to 0.33).
(36%) and nonalcoholic fatty liver disease (32%). The major-
ity of patients (59%) were Child-Pugh class A, and median
(IQR)MELD scorewas 10 (8–15).Therewere no differences in
baseline characteristics between carvedilol and propranolol
groups. 19 out of 22 participants had both baseline and repeat
MRI scans (1 patient died from complications of cirrhosis
during the study; 2 patients were unable to tolerate NSBB,
both on propranolol). Target NSBB dose was achieved in 82%
overall, but more frequently with carvedilol (100% carvedilol
versus 64% propranolol; 𝑃 = 0.03). A greater than 25%
reduction in resting HR was achieved in 47% of participants
who completed the study (56% in propranolol group and 40%
in carvedilol group).
3.2. Quantification of the Regional and Visceral Blood Flow.
There was excellent interobserver agreement for average
blood flow assessment (Pearson correlation coefficient 1.0,
𝑃 < 0.0001, and Bland-Altman analysis, Figure 1).
There was a substantial reduction from baseline in mean
average blood flow in the superior abdominal aorta after 4
weeks of NSBB therapy (4.49 ± 0.98 versus 3.83 ± 0.86 L/min,
𝑃 = 0.029; 𝑛 = 19; Table 2). In all other vessels, there was a
downward trend in mean average flow after 4 weeks of NSBB
therapy, although the reduction in flow was not statistically
significant. In the HR responders, there was a significant
reduction in mean average blood flow in the superior and
inferior aorta (𝑛 = 9; Figure 2). There were no appreciable
differences in blood flow changes between carvedilol and
propranolol treated patients (Figure 3).
3.3. Liver and Spleen T1 Mapping. There was a strong agree-
ment between the 2methods (histogramandROI) to estimate
liver and spleenT1 values (Spearman’s Rho= 0.98 for liver and
0.95 for spleen, 𝑃 < 0.001 for both, 𝑛 = 15). Representative
screen shots of the axial T1 relaxation maps are shown in
Figure 4. Overall, there was no consistent trend of change
in liver or spleen T1 after 4 weeks of NSBB (Figure 5). There
was no clear correlation between changes in liver T1 against
spleen T1 (𝑛 = 15) (Figure 5(c)). The range of changes in T1
were similar in absolute values between the liver (1.2–193ms)
and spleen (18.5–99.2ms).Themean ± SD percentage change
in liver and spleen T1 following NSBB was small and highly
variable (7.67 ± 6.8 for liver and 3.88 ± 2.6 for spleen).
4. Discussion
This is the first study to use PC-MRAas a noninvasive readout
of response in an interventional study of the pharmacological
treatment for PHT. Previous research has shown that this
technique is reproducible and reliable [9, 11, 22, 23]. Impor-
tantly, all patients were able to tolerate the baseline and repeat
scans, including patients with ascites.There were no reported
adverse reactions to gadolinium contrast in this group of
patients with advanced liver disease. We were able to obtain
good quality flowmeasurements in all patients and all vessels
as well as interpretable T1 relaxation maps of liver and spleen
in 79% of patients who had both baseline and 4-week scans.
We confirmed previous reports that NSBB achieve the
target HR response in around 50% of patients (47% overall
in our study). The issue of compliance with medication
was addressed by weekly monitoring (in person and via
telephone) for the duration of the trial and supported by the
fact that all 19 patients that completed the study achieved
a significant reduction between baseline and 4-week HR
(paired t-test 𝑃 < 0.0001).
In this study, PC-MRA was able to detect a significant
reduction in cardiac output by NSBB (as measured by
superior aortic flow). This is a predictable effect of NSBB
and, reassuringly, provides validation of the use of the PC-
MRA methodology in this population. However, PC-MRA
did not detect statistically significant changes in blood flow
in other vessels, such as the expected reduction in portal
inflow and splanchnic vasoconstriction.Thismay simply be a
reflection of the small sample size for this study. Additionally,
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Figure 2: Individual PC-MRA derived blood flow measurements in heart rate responders at baseline and after 4 weeks of NSBB therapy
(𝑛 = 9).There was a significant reduction in the blood flow in superior and inferior aorta after 4 weeks of NSBB therapy (𝑃 < 0.001 and 0.010,
resp.). The changes in flow in all other vessels were not statistically significant. Data analysed by paired t-test.
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SD and analysed by paired t-test; ∗𝑃 < 0.05, ns: not significant. SMA: superior mesenteric artery.
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Figure 5: Absolute change in liver (a) and spleen (b) T1 (delta T1) after 4 weeks of NSBB therapy. Correlation of changes in delta T1 between
liver and spleen (c).There was no consistent increase or decrease in liver or splenic T1 values as a result of NSBB treatment. In addition, there
was no clear correlation found between changes in liver T1 and splenic T1. Bland-Altman analysis.
the HR responders showed a significant reduction in the
average flow in the inferior aorta and a nonsignificant trend
towards decrease in flow in all other vessels, again suggesting
that a larger study may have shown larger and significant
haemodynamic effects. Furthermore, it is also possible that
the known variable clinical efficacy of NSBB contributed to
the interpretation of results, especially since reduction in HR
has previously not been found to correlate strongly with the
HVPG response [24]. To establish, definitively, whether PC-
MRA has sufficient sensitivity to monitor the response to
NSBB, a larger study with concurrent HVPG measurements
and/or clinical outcomes will be required.
The lack of a significant and consistent change in liver
T1 values may be due to the relatively short interval between
the 2 scans, thus not allowing sufficient time for remodelling
of hepatic extracellular matrix that may occur as a result
of proposed antifibrotic and/or anti-inflammatory effect of
carvedilol. The absence of concurrent T2∗ mapping, which
allows an iron correction to be applied to T1 values [21], may
also be relevant, although significant intrasubject variation
in tissue iron concentration during the 4-week follow-up
period seems unlikely. In this study, T1 relaxation mapping
was unable to detect reduction in liver and spleen perfusion,
expected as a result of haemodynamic effects of NSBB. This
could be due to either the lack of significant effect of NSBB
on visceral blood flow or the dominant contribution of the
liver/spleen fibrosis to the T1 readout and consequent lack of
sensitivity of this technique to the changes in blood volume.
5. Conclusions
In this initial feasibility study, PC-MRA was able to detect a
robust reduction in cardiac output by NSBB (as measured by
superior aortic flow) but did not detect significant changes in
visceral blood flow or T1 relaxation time in liver and spleen.
A larger study, evaluating NSBB or TIPSS by PC-MRA and
contemporaneous HVPG measurement, is now required to
determine the true value of noninvasive MRI in this setting.
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